UK vaccine injury scheme denies paralysed trial nurse the payout after admitting the jab caused her condition

Marie-Claire Hoyle, an NHS nurse and England's network manager for high-consequence infectious diseases, volunteered for the AstraZeneca COVID-19 vaccine trial in 2020. Two weeks after her second dose she developed transverse myelitis — inflammation of the spinal cord — losing the use of her hands and going numb from her collarbone to her thigh. Her case paused the global trial while investigators assessed whether the vaccine was responsible. They concluded it was.

The UK's Vaccine Damage Payment Scheme agreed: the vaccine caused her condition. It then refused her the £120,000 one-off payment anyway, because her disability had improved below the scheme's rigid 60 percent lifelong threshold. 'You aren't now, so you don't need the payment,' she was told. Her MRI still shows permanent spinal cord damage; she has poor grip, drops things constantly, and lives with nerve pain she says will never resolve. A high five-figure settlement from Oxford University, which ran the trial, was apparently not subject to any disability bar.

The pattern is structural, not accidental. Manufacturers enjoyed broad immunity during the rollout; the state carried the residual risk through the VDPS, and wrote the terms so almost nobody collects. By 30 June 2026, more than 24,260 COVID-related claims had reached the scheme. Only 264 resulted in awards — just over one percent. Roughly 580 to 603 claims had causation accepted by medical assessors and still failed the 60 percent bar, leaving people with confirmed vaccine injuries and nothing.

Baroness Hallett's COVID-19 Inquiry Module 4 report, published in April 2026, called the scheme 'not sufficiently supportive' and recommended scrapping or softening the threshold, graduated payments by degree of injury, and raising the £120,000 figure to over £200,000 in line with inflation. The government published its response on 16 October 2026: it accepted the need for reform, committed to a review to make the scheme 'fit for purpose', and noted concerns about administrative costs. Hoyle, a mother of three who later had her youngest child vaccinated and still supports vaccination in principle, wants what the inquiry asked for — payments scaled to actual ongoing harm rather than an all-or-nothing cutoff.

AstraZeneca withdrew its Vaxzevria vaccine worldwide in 2024, citing commercial reasons and updated formulations. UK records count 445 confirmed cases of vaccine-induced thrombosis with thrombocytopenia and 81 deaths.